News

Building on Apotex's legacy of giving, including Apotex's global medicine donation program, the Apotex Global Health Access Fund launches with a focus on addressing unequal access to care and low health literacy within communities where there are poor social determinants of health, and where race, economic status, and other factors are barriers to access.

Apotex has initiated a voluntary Type I recall to the Pharmacy Level for twenty-seven (27) lots of “APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP)”. There have been no reports of relevant adverse event or complaints received for any of these twenty-seven (27) lots between November 1, 2019 and October 9, 2024.

Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced an agreement with Formosa Pharmaceuticals ("Formosa") under which Apotex has the exclusive rights to market and distribute APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) in Canada upon approval. The agreement further expands Apotex's ophthalmic franchise, building off a licensing agreement with Harrow Inc. for five branded pharmaceutical products completed in February 2024.

Toripalimab becomes Apotex's first novel brand biologic medicine.

Acquisition marks a significant step in Apotex's growth strategy, advancing its position as a preferred Health Partner of Choice in the Americas.

Canada's largest pharmaceutical company, Apotex Inc. ("Apotex") and Searchlight Pharma Inc. ("Searchlight"), one of Canada's fastest growing companies, announced today that they have reached an agreement whereby Apotex will acquire Searchlight.

Harrow, Inc., a leading U.S. eyecare pharmaceutical company, and Apotex Inc., Canada’s largest pharmaceutical company, today jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter (OTC) Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®.

Investment from SK Capital to support Apotex’s next phase of growth and continued innovation for patient affordability

Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-Apixaban^™ tablets, Canada's first generic alternative to Eliquis^®